Proteon Therapeutics Inc (PRTO) Receives $3.00 Consensus Price Target from Brokerages
Proteon Therapeutics Inc (NASDAQ:PRTO) has been given an average rating of “Buy” by the six research firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $3.00.
A number of brokerages have commented on PRTO. Brookline Cap M restated a “buy” rating on shares of Proteon Therapeutics in a research note on Tuesday, June 26th. Zacks Investment Research upgraded shares of Proteon Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Wednesday, July 11th.
A hedge fund recently raised its stake in Proteon Therapeutics stock. Renaissance Technologies LLC lifted its position in Proteon Therapeutics Inc (NASDAQ:PRTO) by 29.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 306,481 shares of the biopharmaceutical company’s stock after acquiring an additional 70,381 shares during the quarter. Renaissance Technologies LLC owned approximately 1.73% of Proteon Therapeutics worth $751,000 at the end of the most recent reporting period. Institutional investors own 50.56% of the company’s stock.
Proteon Therapeutics (NASDAQ:PRTO) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.08. On average, equities research analysts forecast that Proteon Therapeutics will post -1.2 earnings per share for the current fiscal year.
About Proteon Therapeutics
Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes.
Further Reading: Cash Flow
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.